Literature DB >> 20160054

Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.

Joaquín Rullas1, Juan Ignacio García, Manuela Beltrán, Pere-Joan Cardona, Neus Cáceres, José Francisco García-Bustos, Iñigo Angulo-Barturen.   

Abstract

Murine models of Mycobacterium tuberculosis infection are essential tools in drug discovery. Here we describe a fast standardized 9-day acute assay intended to measure the efficacy of drugs against M. tuberculosis growing in the lungs of immunocompetent mice. This assay is highly reproducible, allows good throughput, and was validated for drug lead optimization using isoniazid, rifampin, ethambutol, pyrazinamide, linezolid, and moxifloxacin.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20160054      PMCID： PMC2863680          DOI： 10.1128/AAC.01423-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  A method of endotracheal intubation and pulmonary functional assessment for repeated studies in mice.

Authors:  R H Brown; D M Walters; R S Greenberg; W Mitzner
Journal:  J Appl Physiol (1985)       Date:  1999-12

2.  Replication dynamics of Mycobacterium tuberculosis in chronically infected mice.

Authors:  Ernesto J Muñoz-Elías; Juliano Timm; Tania Botha; Wai-Tsing Chan; James E Gomez; John D McKinney
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 3.  Preclinical study of new TB drugs and drug combinations in mouse models.

Authors:  Boris V Nikonenko; Katherine A Sacksteder; Sam Hundert; Leo Einck; Carol A Nacy
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2008-06

Review 4.  Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs.

Authors:  G R Davies; E L Nuermberger
Journal:  Tuberculosis (Edinb)       Date:  2008-08       Impact factor: 3.131

5.  Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.

Authors:  Boris V Nikonenko; Rowena Samala; Leo Einck; Carol A Nacy
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice.

Authors:  Anne J M Lenaerts; Veronica Gruppo; Jason V Brooks; Ian M Orme
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

7.  Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity.

Authors:  Alissa A Chackerian; Jennifer M Alt; Thushara V Perera; Christopher C Dascher; Samuel M Behar
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

8.  Animal models of tuberculosis.

Authors:  Douglas Young
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

9.  OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Authors:  Makoto Matsumoto; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Hidetsugu Tsubouchi; Hirofumi Sasaki; Yoshihiko Shimokawa; Makoto Komatsu
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

10.  Disseminated tuberculosis in interferon gamma gene-disrupted mice.

Authors:  A M Cooper; D K Dalton; T A Stewart; J P Griffin; D G Russell; I M Orme
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307
View more
  36 in total

1.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence.

Authors:  Jee-Hyun Kim; Kathryn M O'Brien; Ritu Sharma; Helena I M Boshoff; German Rehren; Sumit Chakraborty; Joshua B Wallach; Mercedes Monteleone; Daniel J Wilson; Courtney C Aldrich; Clifton E Barry; Kyu Y Rhee; Sabine Ehrt; Dirk Schnappinger
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

3.  Testing tuberculosis drug efficacy in a zebrafish high-throughput translational medicine screen.

Authors:  Anita Ordas; Robert-Jan Raterink; Fraser Cunningham; Hans J Jansen; Malgorzata I Wiweger; Susanne Jong-Raadsen; Sabine Bos; Robert H Bates; David Barros; Annemarie H Meijer; Rob J Vreeken; Lluís Ballell-Pages; Ron P Dirks; Thomas Hankemeier; Herman P Spaink
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

4.  Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.

Authors:  Delia Blanco; Esther Perez-Herran; Mónica Cacho; Lluís Ballell; Julia Castro; Rubén González Del Río; José Luis Lavandera; Modesto J Remuiñán; Cindy Richards; Joaquin Rullas; María Jesús Vázquez-Muñiz; Ermias Woldu; María Cleofé Zapatero-González; Iñigo Angulo-Barturen; Alfonso Mendoza; David Barros
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

5.  Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Janet C Gilliland; Colby L Wells; Elizabeth J Brooks; Lisa K Woolhiser; Veronica Gruppo; Charles A Peloquin; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

6.  A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.

Authors:  Christopher P Locher; Steven M Jones; Brian L Hanzelka; Emanuele Perola; Carolyn M Shoen; Michael H Cynamon; Andile H Ngwane; Ian J Wiid; Paul D van Helden; Fabrice Betoudji; Eric L Nuermberger; John A Thomson
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

7.  Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic.

Authors:  Neeraj Dhar; Vincent Dubée; Lluis Ballell; Guillaume Cuinet; Jean-Emmanuel Hugonnet; François Signorino-Gelo; David Barros; Michel Arthur; John D McKinney
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

8.  Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.

Authors:  Jean-Philippe Lanoix; Thomas Ioerger; Aimee Ormond; Firat Kaya; James Sacchettini; Véronique Dartois; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

9.  A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis.

Authors:  Anuradha Kumar; Ana Guardia; Gonzalo Colmenarejo; Esther Pérez; Ruben R Gonzalez; Pedro Torres; David Calvo; Ruben M Gómez; Fátima Ortega; Elena Jiménez; Raquel C Gabarro; Joaquín Rullás; Lluis Ballell; David R Sherman
Journal:  ACS Infect Dis       Date:  2015-08-12       Impact factor: 5.084

10.  A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.

Authors:  Daigo Inoyama; Divya Awasthi; Glenn C Capodagli; Kholiswa Tsotetsi; Paridhi Sukheja; Matthew Zimmerman; Shao-Gang Li; Ravindra Jadhav; Riccardo Russo; Xin Wang; Courtney Grady; Todd Richmann; Riju Shrestha; Liping Li; Yong-Mo Ahn; Hsin Pin Ho Liang; Marizel Mina; Steven Park; David S Perlin; Nancy Connell; Véronique Dartois; David Alland; Matthew B Neiditch; Pradeep Kumar; Joel S Freundlich
Journal:  Cell Chem Biol       Date:  2020-03-19       Impact factor: 8.116
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.